MKA
ABBV icon

M. Kulyk & Associates’s AbbVie ABBV Stock Holding History

M. Kulyk & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$968K Sell
3,846
-89
-2% -$19.1K 0.16% 59
2026
Q1 		$856K Buy
3,935
+13
+0.3% +$2.88K 0.16% 59
2025
Q4 		$896K Sell
3,922
-12
-0.3% -$2.73K 0.17% 56
2025
Q3 		$911K Buy
3,934
+132
+3% +$26.9K 0.19% 53
2025
Q2 		$706K Sell
3,802
-232
-6% -$43.1K 0.15% 62
2025
Q1 		$845K Buy
4,034
+30
+0.7% +$5.83K 0.19% 58
2024
Q4 		$712K Sell
4,004
-852
-18% -$157K 0.15% 63
2024
Q3 		$959K Buy
4,856
+127
+3% +$23.7K 0.19% 58
2024
Q2 		$811K Hold
4,729
– – 0.19% 58
2024
Q1 		$861K Sell
4,729
-125
-3% -$21.5K 0.2% 57
2023
Q4 		$752K Hold
4,854
– – 0.18% 61
2023
Q3 		$724K Sell
4,854
-212
-4% -$31.1K 0.2% 58
2023
Q2 		$683K Sell
5,066
-37
-0.7% -$5.43K 0.19% 62
2023
Q1 		$813K Sell
5,103
-44
-0.9% -$6.73K 0.25% 59
2022
Q4 		$832K Buy
5,147
+75
+1% +$11.5K 0.28% 60
2022
Q3 		$681K Hold
5,072
– – 0.24% 61
2022
Q2 		$777K Sell
5,072
-442
-8% -$67.5K 0.24% 54
2022
Q1 		$894K Buy
5,514
+295
+6% +$42.9K 0.24% 54
2021
Q4 		$707K Buy
5,219
+2,834
+119% +$335K 0.18% 54
2021
Q3 		$257K Buy
2,385
+150
+7% +$17.1K 0.08% 64
2021
Q2 		$252K Sell
2,235
-10
-0.4% -$1.13K 0.09% 59
2021
Q1 		$243K Buy
+2,245
New +$240K 0.09% 64

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

M. Kulyk & Associates's ABBV Position: Q2 2026 in Review

M. Kulyk & Associates reduced its AbbVie (ABBV) stake by 2.3% in Q2 2026, selling an estimated $19.1K and leaving 3,846 shares worth $968K. The position accounts for 0.16% of the portfolio, ranked #59.

M. Kulyk & Associates first reported a position in ABBV in Q1 2021 and has held it in 22 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • M. Kulyk & Associates held 3,846 shares of AbbVie worth $968K as of Q2 2026.
  • M. Kulyk & Associates sold 89 AbbVie shares in Q2 2026, an estimated $19.1K.
  • AbbVie made up 0.16% of M. Kulyk & Associates's portfolio in Q2 2026, its #59 holding.
  • M. Kulyk & Associates first reported a position in AbbVie in Q1 2021 and has held it in 22 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on M. Kulyk & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.